Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Section 6 of 6

References

209 sources

  1. ADARx Pharmaceuticals prospectus (2026) (opens in a new tab)
  2. Adatia et al. (2026) (opens in a new tab)
  3. Anderson et al. (2025a) (opens in a new tab)
  4. Anderson et al. (2025b) (opens in a new tab)
  5. Anderson et al. (2026a) (opens in a new tab)
  6. Anderson et al. (2026b) (opens in a new tab)
  7. Anderson et al. (2026c) (opens in a new tab)
  8. Arora et al. (2023) (opens in a new tab)
  9. Aygören-Pürsün et al. (2014) (opens in a new tab)
  10. Aygören-Pürsün et al. (2016) (opens in a new tab)
  11. Aygören-Pürsün et al. (2026a) (opens in a new tab)
  12. Aygören-Pürsün et al. (2026b) (opens in a new tab)
  13. Banta et al. (2011) (opens in a new tab)
  14. Bernstein et al. (2019) (opens in a new tab)
  15. Bernstein et al. (2025) (opens in a new tab)
  16. Betschel et al. (2024) (opens in a new tab)
  17. Betschel et al. (2025) (opens in a new tab)
  18. Betschel et al. (2026) (opens in a new tab)
  19. Blasco et al. (2013) (opens in a new tab)
  20. Bork et al. (2003) (opens in a new tab)
  21. Bork et al. (2006) (opens in a new tab)
  22. Bork et al. (2012) (opens in a new tab)
  23. Bui et al. (2026) (opens in a new tab)
  24. Busse et al. (2021) (opens in a new tab)
  25. Busse et al. (2026) (opens in a new tab)
  26. Buttgereit et al. (2025) (opens in a new tab)
  27. Caballero et al. (2014) (opens in a new tab)
  28. California HCAI five-year WAC increase history (2026) (opens in a new tab)
  29. California HCAI prescription drugs introduced to market (2019) (opens in a new tab)
  30. California HCAI prescription drugs introduced to market (2020) (opens in a new tab)
  31. California HCAI prescription drugs introduced to market (2021) (opens in a new tab)
  32. California HCAI prescription drugs introduced to market (2025) (opens in a new tab)
  33. California HCAI prescription drugs introduced to market (2026) (opens in a new tab)
  34. California HCAI WAC increase data (2024) (opens in a new tab)
  35. California HCAI WAC increase data (2025) (opens in a new tab)
  36. California HCAI WAC increase data (2026) (opens in a new tab)
  37. Cancian et al. (2025) (opens in a new tab)
  38. Castaldo et al. (2021) (opens in a new tab)
  39. Castaldo et al. (2025) (opens in a new tab)
  40. Christiansen et al. (2015) (opens in a new tab)
  41. Christiansen et al. (2023) (opens in a new tab)
  42. Christiansen et al. (2025a) (opens in a new tab)
  43. Christiansen et al. (2025b) (opens in a new tab)
  44. Christiansen et al. (2026) (opens in a new tab)
  45. Cicardi et al. (2010a) (opens in a new tab)
  46. Cicardi et al. (2010b) (opens in a new tab)
  47. Cigna Ekterly drug quantity management policy (2026) (opens in a new tab)
  48. Cigna Ekterly prior authorization policy (2026) (opens in a new tab)
  49. ClinicalTrials.gov NCT04618211 (opens in a new tab)
  50. ClinicalTrials.gov NCT04618211 API record (opens in a new tab)
  51. ClinicalTrials.gov NCT05396105 (opens in a new tab)
  52. ClinicalTrials.gov NCT06343779 (opens in a new tab)
  53. ClinicalTrials.gov NCT07759141 (opens in a new tab)
  54. CMS Clinical Laboratory Fee Schedule (2026) (opens in a new tab)
  55. CMS Medicare Part B payment limit file (2026) (opens in a new tab)
  56. CMS Medicare Part D Spending by Drug (2026) (opens in a new tab)
  57. Cohn et al. (2023) (opens in a new tab)
  58. Cohn et al. (2025) (opens in a new tab)
  59. Cohn et al. (2026) (opens in a new tab)
  60. CountyCare acute HAE products guideline (2026) (opens in a new tab)
  61. Crabbé et al. (2021) (opens in a new tab)
  62. Craig et al. (2009) (opens in a new tab)
  63. Craig et al. (2021) (opens in a new tab)
  64. Craig et al. (2026a) (opens in a new tab)
  65. Craig et al. (2026b) (opens in a new tab)
  66. CSL Behring (2022) (opens in a new tab)
  67. CSL Behring BERINERT prescribing information (2021) (opens in a new tab)
  68. CTIS.eu 2023-506305-18-01 (opens in a new tab)
  69. CTIS.eu 2024-514713-35-00 (opens in a new tab)
  70. Cycle SAJAZIR prescribing information (2024) (opens in a new tab)
  71. Danielsson et al. (2025) (opens in a new tab)
  72. Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026) (opens in a new tab)
  73. Derendorf et al. (2020) (opens in a new tab)
  74. EMA orphan designation EU/3/25/3040 (2025) (opens in a new tab)
  75. EMA paediatric investigation plan decision P/0411/2023 (2023) (opens in a new tab)
  76. EMA paediatric investigation plan modification EMA/PE/0000227462 (2025) (opens in a new tab)
  77. EU Clinical Trials Register 2021-006906-58 (opens in a new tab)
  78. Farkas et al. (2025) (opens in a new tab)
  79. Farkas et al. (2026) (opens in a new tab)
  80. FDA (2022) (opens in a new tab)
  81. FDA ANDEMBRY prescribing information (2025) (opens in a new tab)
  82. FDA DAWNZERA prescribing information (2025) (opens in a new tab)
  83. FDA Drug Trials Snapshot EKTERLY (opens in a new tab)
  84. FDA ORLADEYO prescribing information (2026) (opens in a new tab)
  85. FDA Orphan Drug Designations and Approvals (2022) (opens in a new tab)
  86. FDA TAKHZYRO prescribing information (2026) (opens in a new tab)
  87. Federici et al. (2018) (opens in a new tab)
  88. Fijen et al. (2023) (opens in a new tab)
  89. Fisch et al. (2025) (opens in a new tab)
  90. G-BA sebetralstat resolution justification (2026) (opens in a new tab)
  91. Gallop et al. (2026) (opens in a new tab)
  92. Groen et al. (2021) (opens in a new tab)
  93. Grover et al. (2022) (opens in a new tab)
  94. Grumach et al. (2026) (opens in a new tab)
  95. Guan et al. (2024) (opens in a new tab)
  96. HAS EKTERLY transparency committee opinion (2026) (opens in a new tab)
  97. Henao et al. (2016) (opens in a new tab)
  98. Heuring et al. (2026) (opens in a new tab)
  99. Hummel et al. (2026) (opens in a new tab)
  100. ICER final evidence report (2018) (opens in a new tab)
  101. Intellia Therapeutics AAAAI poster (2026) (opens in a new tab)
  102. Jacobs et al. (2025) (opens in a new tab)
  103. KalVista EKTERLY prescribing information (2025) (opens in a new tab)
  104. KalVista Pharmaceuticals Colorado WAC disclosure (2026) (opens in a new tab)
  105. Kawalec et al. (2013) (opens in a new tab)
  106. Khalid and Hitch (2025) (opens in a new tab)
  107. Kim et al. (2014) (opens in a new tab)
  108. Kinaciyan et al. (2026) (opens in a new tab)
  109. Kutrieb et al. (2026) (opens in a new tab)
  110. Leibovich-Nassi et al. (2023) (opens in a new tab)
  111. Lesage et al. (2020) (opens in a new tab)
  112. Lesage et al. (2021) (opens in a new tab)
  113. Lesage et al. (2022) (opens in a new tab)
  114. Lesage et al. (2026a) (opens in a new tab)
  115. Lesage et al. (2026b) (opens in a new tab)
  116. Leung et al. (2026) (opens in a new tab)
  117. Levy et al. (2010) (opens in a new tab)
  118. Li et al. (2023) (opens in a new tab)
  119. Li et al. (2025) (opens in a new tab)
  120. Lo et al. (2022) (opens in a new tab)
  121. Lochbaum et al. (2026) (opens in a new tab)
  122. Longhurst et al. (2024) (opens in a new tab)
  123. Lu et al. (2020) (opens in a new tab)
  124. Lumry et al. (2010) (opens in a new tab)
  125. Lumry et al. (2011) (opens in a new tab)
  126. Lumry et al. (2025) (opens in a new tab)
  127. Maurer et al. (2013) (opens in a new tab)
  128. Maurer et al. (2022) (opens in a new tab)
  129. Maurer et al. (2023a) (opens in a new tab)
  130. Maurer et al. (2023b) (opens in a new tab)
  131. Maurer et al. (2026) (opens in a new tab)
  132. McMillan et al. (2012) (opens in a new tab)
  133. MedlinePlus (opens in a new tab)
  134. Meisgen et al. (2026) (opens in a new tab)
  135. Mendivil et al. (2021) (opens in a new tab)
  136. Mendivil et al. (2026) (opens in a new tab)
  137. Minafra et al. (2022a) (opens in a new tab)
  138. Minafra et al. (2022b) (opens in a new tab)
  139. MO HealthNet Ekterly fact blast (2025) (opens in a new tab)
  140. NICE sebetralstat draft guidance (2025) (opens in a new tab)
  141. NICE sebetralstat project page (2026) (opens in a new tab)
  142. O'Connor et al. (2025) (opens in a new tab)
  143. Olson et al. (2026) (opens in a new tab)
  144. Onderzoekmetmensen.nl NL-OMON49496 (opens in a new tab)
  145. Onderzoekmetmensen.nl NL-OMON49587 (opens in a new tab)
  146. Petersen et al. (2024) (opens in a new tab)
  147. Pharming RUCONEST prescribing information (2020) (opens in a new tab)
  148. Pharvaris 2025 strategic priorities press release (2025) (opens in a new tab)
  149. Pharvaris 2026 strategic priorities press release (2026) (opens in a new tab)
  150. Pharvaris AAAAI 2026 press release (2026) (opens in a new tab)
  151. Pharvaris ACAAI 2020 press release (2020) (opens in a new tab)
  152. Pharvaris CIIC Spring 2026 press release (2026) (opens in a new tab)
  153. Pharvaris clinical hold press release (2022) (opens in a new tab)
  154. Pharvaris corporate presentation, January 2024 (2024) (opens in a new tab)
  155. Pharvaris EAACI 2026 press release (2026) (opens in a new tab)
  156. Pharvaris Form 20-F (2026) (opens in a new tab)
  157. Pharvaris Form 6-K, first quarter 2025 results (2025) (opens in a new tab)
  158. Pharvaris Form 6-K, first quarter 2026 results (2026) (opens in a new tab)
  159. Pharvaris Form 6-K, fourth quarter and full year 2025 results (2026) (opens in a new tab)
  160. Pharvaris Form 6-K, second quarter 2025 results (2025) (opens in a new tab)
  161. Pharvaris Form 6-K, second quarter 2026 results (2026) (opens in a new tab)
  162. Pharvaris Form 6-K, third quarter 2026 MD&A (2026) (opens in a new tab)
  163. Pharvaris Form 6-K, third quarter 2026 results (2026) (opens in a new tab)
  164. Pharvaris Form F-1/A registration statement (2021) (opens in a new tab)
  165. Pharvaris NDA acceptance press release (2026) (opens in a new tab)
  166. Pharvaris RAPIDe-1 topline press release (2022) (opens in a new tab)
  167. Pharvaris RAPIDe-3 Lancet publication press release (2026) (opens in a new tab)
  168. Pharvaris RAPIDe-3 topline data presentation (2025) (opens in a new tab)
  169. Pharvaris RAPIDe-3 topline press release (2025) (opens in a new tab)
  170. Pharvaris RAPIDe-3 topline timing update press release (2025) (opens in a new tab)
  171. Princic et al. (2025) (opens in a new tab)
  172. Regence medication policy dru535 (2026) (opens in a new tab)
  173. Riedl et al. (2014) (opens in a new tab)
  174. Riedl et al. (2018) (opens in a new tab)
  175. Riedl et al. (2023a) (opens in a new tab)
  176. Riedl et al. (2023b) (opens in a new tab)
  177. Riedl et al. (2023c) (opens in a new tab)
  178. Riedl et al. (2024) (opens in a new tab)
  179. Riedl et al. (2026a) (opens in a new tab)
  180. Riedl et al. (2026b) (opens in a new tab)
  181. Riedl et al. (2026c) (opens in a new tab)
  182. Sandberg et al. (2024) (opens in a new tab)
  183. Shah et al. (2023) (opens in a new tab)
  184. Sundler Björkman et al. (2022) (opens in a new tab)
  185. Tachdjian et al. (2024) (opens in a new tab)
  186. Tachdjian et al. (2026) (opens in a new tab)
  187. Takeda FIRAZYR prescribing information (2024) (opens in a new tab)
  188. Takeda KALBITOR prescribing information (2020) (opens in a new tab)
  189. Troelnikov et al. (2024) (opens in a new tab)
  190. Univera Healthcare hereditary angioedema pharmacy policy (2026) (opens in a new tab)
  191. US Hereditary Angioedema Association (opens in a new tab)
  192. US Hereditary Angioedema Association treatment guidelines (opens in a new tab)
  193. Valerieva et al. (2023) (opens in a new tab)
  194. Valerieva et al. (2024) (opens in a new tab)
  195. Vázquez et al. (2026) (opens in a new tab)
  196. Vernon et al. (2009) (opens in a new tab)
  197. Watt et al. (2026a) (opens in a new tab)
  198. Watt et al. (2026b) (opens in a new tab)
  199. Wilson et al. (2010) (opens in a new tab)
  200. Wong et al. (2022) (opens in a new tab)
  201. World Health Organization (2021) (opens in a new tab)
  202. Yong et al. (2023) (opens in a new tab)
  203. Yong et al. (2025) (opens in a new tab)
  204. Zanichelli et al. (2015) (opens in a new tab)
  205. Zhang et al. (2025) (opens in a new tab)
  206. Zilberberg et al. (2010) (opens in a new tab)
  207. Zilberberg et al. (2011) (opens in a new tab)
  208. Zuraw and Christiansen (2026) (opens in a new tab)
  209. Zuraw et al. (2010) (opens in a new tab)